Antitumor activity of imatinib mesylate in neuroblastoma xenografts

Daniela Meco, Anna Shirley Riccardi, Tiziana Servidei, Marco Gessi, Riccardo Riccardi, Josef Brueggen, Carlo Dominici

Risultato della ricerca: Contributo in rivistaArticolo in rivista

21 Citazioni (Scopus)

Abstract

Imatinib mesylate has antitumor activity in vitro and in vivo against neuroblastoma cell lines and xenografts characterized by a different expression of receptor tyrosine kinases. In this article, we report that imatinib tumor concentration can be independent of the administered dose and does not correlate with the antitumor effect. In xenografts, high-dose administration does not improve imatinib efficacy. In conclusion, there is no clear-cut correlation between the levels of expression for imatinib-responsive targets and the in vitro and in vivo sensitivity. This further suggests that in neuroblastoma the antitumor activity of imatinib may involve the inhibition of other tyrosine kinases and/or pathways.
Lingua originaleEnglish
pagine (da-a)211-219
Numero di pagine9
RivistaCancer Letters
Volume228
Stato di pubblicazionePubblicato - 2005

Keywords

  • PDGFR
  • imatinib mesylate
  • neuroblastoma
  • receptor tyrosine kinase
  • xenografts

Fingerprint Entra nei temi di ricerca di 'Antitumor activity of imatinib mesylate in neuroblastoma xenografts'. Insieme formano una fingerprint unica.

Cita questo